// App-Quantinova.ai

POS0003 (2022) : DEVELOPMENT AND VALIDATION OF A DISEASE SPECIFIC PATIENT REPORTED OUTCOME FOR GIANT CELL ARTERITIS

Researchers

Presenter

  • J. Robson

Principal Investigators

  • C. Almeida

  • J. Dawson

  • E. Dures

  • R. Greenwood

  • C. Guly

  • S. Mackie

  • A. Bromhead

  • S. Stern

  • M. Ndosi

Medical Centers

  • University of the West of England - UWE Bristol, Health and Social Wellbeing, Stoke Gifford, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, United Kingdom

  • University of Oxford, Old Road Campus, Department of Public Health, Oxford, United Kingdom

  • University of Leeds, Leeds Institue of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

  • Leeds General Infirmary, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Obstetrics/Gynecology

Disease

  • Giant cell arteritis

  • Preterm premature rupture of the membranes

Biomarkers

  • N/A

Drug/Treatment

  • Glucocorticoid

Outcome

  • N/A

Study Design

  • Cross-Sectional

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Vifor Pharma Steroid Pro

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved